China is now an industry buzzword when it comes to outsourcing and
yet another report adds to the list of research recently published
that give evidence of the increasing popularity of the country as a
location to conduct drug clinical...
Singapore is planning to double the number of clinical trials it
runs over the next five year, particularly in early phase research,
as it looks to hold its ground amidst industry explosion in the
Asia Pacific.
The nature of patient compliance as the weak link in controlling
clinical trials is set to drive the growing interest of drug
developers and in particular contract research organisations (CROs)
for new technologies that improve compliance,...
Several discontinued drug candidates that target the central
nervous system (CNS) have been given a second chance for success
after Synosis Therapeutics bought them off Roche.
Genentech has shown their faith in a blood cancer drug development
programme by licensing just one compound for up $800m (€615m),
highlighting the willingness of large pharmaceutical companies to
pay large sums for even a single drug...
The use of virtual patients to simulate clinical trials on
computers can forecast their results, potentially optimising drug
development and saving the pharmaceutical industry billions.
Despite the many challenges facing the pharma industry, drug
developers should be optimistic, and one of the reasons is the
increasing reliance on global outsourcing to speed development and
reduce costs, says new report.
Encorium Group has bagged a $12.4m multi-year contract from a
mystery biopharma firm to conduct a Phase III drug trial for
prostate cancer - the most common cancer in men.
Quintiles has formed a new alliance with a hospital near its
headquarters in North Carolina, from where it has begun running
clinical trials on experimental drugs.
Seriously ill patients in the US could soon have greater access to
experimental drugs if a planned regulatory overhaul by the Food and
Drug Administration (FDA) goes ahead.
Vion Pharmaceuticals has awarded a manufacturing agreement with
Ohio based contract manufacturers Ben Venue Laboratories to produce
its lead anticancer drug, Cloretazine (VNP40101M).
Sufferers of Alzheimer's have received a boost with the news that
GlaxoSmithKine has ploughed further investment into developing new
drugs to combat the disease.
According to a review of public healthcare funding, the current
method of developing drugs is unsustainable and must be updated if
the UK is to remain at the forefront of European bioscience.
Three failed clinical trials on two different drug candidates in a
week are bad enough for Bayer but it is their collaborators who are
really suffering.
i3 has announced new plans to expand its pharmaceutical services
offerings across four continents - India, Latin America, and
Eastern and Western Europe.
Before deciding what part of a clinical trial to outsource, one of
the most important things a sponsor should do is define its core
competencies and then outsource accordingly.
Nastech missed out on a $15m (€11m) milestone payment after having
to delay the development of its new nasal spray for the treatment
of osteoporosis because of the need of an additional clinical
trial.
A hefty investment by Pfizer in an Irish manufacturing facility
could prove to be a waste after the potential blockbuster it was
designed to make has been canned.
The contract research organisation (CRO) industry is in full swing
as the clinical trial outsourcing trend continues, but where is the
money being spent?
ReSearch Pharmaceutical Services (RPS), a US based outsourcing
company, has announced expansion plans in Latin America. This
reflects the increasing trend of pharmaceutical companies
exploiting the cost benefits associated with outsourcing...
It has been another few weeks of activity for the budding eClinical
industry as sponsors across the globe continue to move away from
paper toward electronic reporting in clinical trials.
Charles River Laboratories is the latest in a series of large
contract research organisations making acquisitions to beef up
their Phase I capacity as this market sector remains hot.
Canadian drug maker LAB International has announced its plan to
acquire Texan PharmaForm in order to speed up the manufacture of
its inhalable anti-pain drug, which will reach late stage clinical
trials next year.
A white paper that looks at the eClinical business model strategies
has concluded that larger investments and access to multicomponent,
single-source contracting options will create more efficient models
for businesses.
UK-based Synexus Clinical Research is continuing its global
movements with the latest acquisition of South African outfit
Clinical Research Centers (CRC).
US-based drug maker Cleveland BioLabs has teamed up with
biopharmaceutical manufacturer Synco Bio Partners to produce its
leading radioprotection molecule for clinical trials and
commercialisation
Pharma companies that aren't maximising their outsourcing potential
in clinical research may be wasting a world of opportunity.
OutsourcingPharma.com gives a brief run down of exactly what kinds
of services and providers are...
Curalogic, a Danish biotechnology company, has appointed SAFC's
Pharma business segment to provide protein isolation, extraction
and purification services as part of its product development to
treat Allergic Rhinitis.
As it steps up its presence in the major clinical trials
recruitment hubs in Asia, Quintiles has announced its intention to
open a central lab in India to help feed its expanding network of
clinical trial operations in the country.
As the clinical trial activities continue to flock towards emerging
countries such as India, Morocco wants its share has been making
efforts to make itself attractive to international trial sponsors.
Paraxel has acquired a $65m (€52m) US business that will inflate
its early phase capacity enough to make it one of the largest
providers of Phase I services in the world and help "return its US
operations to profitability".
Integrated exploratory protocols could be the way forward in
carrying out early phase clinical studies, which not only reduces
drug development time and cost but minimises risk of late phase
failures.
Falling foul of the patient recruitment problems that are plaguing
the industry, RegeneRx Biopharmaceuticals has recruited an
undisclosed contract research organisation (CRO) to help it with
the mountainous task.
Contract Research Organisations (CROs) have acquired an enviable
reputation for providing a good quality service that is carried out
by experienced staff, delivering all to budget and on time. But is
outsourcing early phase clinical...
